Preexisting immunity to poliovirus does not impair the efficacy of recombinant poliovirus vaccine vectors.
Recombinant viruses are attractive candidates for the development of novel vaccines. A number of viruses have been engineered as vaccine vectors to express antigens from other pathogens or tumors. Inoculation of susceptible animals with this type of recombinant virus results in the induction of both humoral and cellular immune responses directed against the foreign antigens. A general problem to this approach is that existing immunity to the vector can diminish or completely abolish the efficacy of the viral vector. In this study, we investigated whether poliovirus recombinants are capable of inducing effective immunity to the foreign antigen in previously vaccinated animals. Antipoliovirus immunity was induced in susceptible mice by intraperitoneal immunization with live poliovirus. Immunized mice developed antibodies directed against capsid proteins that effectively neutralized poliovirus in vitro and protected animals from a lethal challenge with a high dose of pathogenic poliovirus. To test whether preexisting immunity reduces the efficacy of vaccination with recombinant poliovirus, immunized mice were inoculated with a recombinant poliovirus expressing the C-terminal half of chicken ovalbumin (Polio-Ova). Animals developed ovalbumin-specific antibodies and cytotoxic T lymphocytes (CTL). While the antibody titers observed in preimmune and naive mice were similar, the overall CTL response appeared to be reduced in preimmune mice. Importantly, vaccination with Polio-Ova was able to effectively protect preimmune mice against lethal challenge with a tumor expressing the antigen. Thus, preexisting immunity to poliovirus does not compromise seriously the efficacy of replication-competent poliovirus vaccine vectors. These results contrast with those observed for other viral vaccine vectors and suggest that preexisting immunity does not equally affect the vaccine potential of individual viral vectors.
Mandl
S
S
Department of Microbiology and Immunology, University of California, San Francisco, California 94143, USA.
Hix
L
L
Andino
R
R
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005822:Genetic Vectors / Q000276:immunology* / Q000627:therapeutic use; D007117:Immunization, Secondary; D008545:Melanoma / Q000276:immunology / Q000517:prevention & control; D051379:Mice; D010047:Ovalbumin / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D017955:Poliovirus / Q000235:genetics / Q000276:immunology*; D011055:Poliovirus Vaccine, Oral / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology* / Q000627:therapeutic use
D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral; D014614:Vaccines, Synthetic; D010047:Ovalbumin